TACTILE SYSTEMS TECHNOLOGY INC (TCMD): Results of Operations and Financial Condition
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tcmd-20260810xex99d1.htm EX-99.1 Exhibit 99.1 Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology com
How this was made
The 30-second read
Why it matters
For TCMD, the key tradable elements are the Q2 earnings metrics (revenue, gross margin, net income, adjusted EBITDA) and the revised full-year revenue range, which management links to near-term inventory management at large DME providers during the next-generation AffloVest launch.
Market read
TCMD’s guidance update and the explicit explanation of airway-clearance ordering conservatism provide a near-term catalyst for valuation and positioning.
What to watch
Cash declined to $69.9M from $83.4M despite no debt, so traders may watch working-capital swings around the AffloVest launch and repurchase pace.
Background
Tactile Systems Technology (Tactile Medical) filed an SEC 8-K with Q2 2026 financial results and an updated 2026 outlook, alongside product and distribution updates.
Ticker impact
TCMD reported Q2 2026 results and updated full-year revenue guidance to $360M-$366M, citing inventory dynamics around next-gen AffloVest.
Likely near-term positive bias from higher revenue, net income, and adjusted EBITDA, partially offset by the more conservative airway-clearance ordering outlook.
The filing includes specific Q2 financials (revenue, gross margin, net income, adjusted EBITDA) and a revised 2026 revenue range, explicitly attributing the change to DME inventory levels during the AffloVest launch.
Market effects
Adds datapoints for medical device/therapeutics demand visibility, especially for lymphedema and airway clearance modalities tied to DME inventory cycles.
No specific regional market impact beyond US distribution rights and VA/DoD commercialization.
Primarily US-focused distribution and ordering dynamics; limited direct global read-through.
Counterpoint
The revenue growth and margin expansion may be partly timing-driven, with airway-clearance weakness reflecting temporary channel digestion rather than durable demand.
Key entities
- issuerTactile Systems Technology, Inc.
Nasdaq-listed medical technology company reporting Q2 2026 results and updating 2026 guidance.
- partnerElastiMed, Inc.
Entered into an exclusive U.S. distribution agreement with TCMD for MyoSleeve distribution to Veterans and active-duty service members.
- portfolio integrationLymphaTech
TCMD advanced integration activities to expand its lymphedema care continuum.
- customer/channelDepartment of Veterans Affairs and Department of Defense
TCMD secured exclusive distribution rights for MyoSleeve.
